Artbio Is A Clinical Stage Radiopharmaceutical Company Focused On Advancing Cancer Care Through The Development Of Alpha Radioligand Therapiesarts Founded In 2021The Company Aims To Create Targeted Cancer Treatments By Combining Alpha Emitting Isotopes With Ligands That Target Specific Tumor Markersartbio S Approach Integrates A Deep Understanding Of Cancer Biology With The Infrastructure Needed For Designingmanufacturingand Distributing These Therapies The Company S Lead Programab001Is Being Developed For Prostate Cancer Treatmentartbio Is Also Innovating With Its Pb 212 Isolation Technology Alphadirect Tm To Enhance The Production And Distribution Of Alpha Emitting Isotopeswith Significant Funding From Partners Like F Prime Capital And Omega Fundsartbio Is Building A Comprehensive Ecosystem To Ensure Effective Delivery Of Its Therapies To Eligible Patientsemphasizing A Patient Centric Approach In Its Mission To Improve Cancer Treatment Outcomes
